Search results
We Discuss Why BioNTech SE's (NASDAQ:BNTX) CEO Will Find It Hard To Get A Pay Rise From Shareholders...
Simply Wall St. via Yahoo Finance· 2 weeks agoKey Insights BioNTech will host its Annual General Meeting on 17th of May CEO Ugur Sahin's total...
BioNTech's Ready-to-Use Single Dose Vaccine, the Perfect Counterattack to China's Rising XBB1.5...
Benzinga via Yahoo Finance· 1 year agoIn an annual general meeting, BioNTech SE's (NASDAQ: BNTX) CEO and co-founder Ugur Sahin told...
Cancer vaccine could be available before 2030, says scientist couple behind COVID-19 shot
Business Insider via Yahoo News· 2 years agoAn employee holds up a vial of an oncological product under development, at the BioNTech research...
BioNTech SE (NASDAQ:BNTX) stock most popular amongst private equity firms who own 44%, while...
Simply Wall St. via Yahoo Finance· 1 year agoA look at the shareholders of BioNTech SE (NASDAQ:BNTX) can tell us which group is most powerful....
Individual investors own 21% of BioNTech SE (NASDAQ:BNTX) shares but private equity firms control...
Simply Wall St. via Yahoo Finance· 1 year agoIf you want to know who really controls BioNTech SE (NASDAQ:BNTX), then you'll have to look at the...
BioNTech reports net loss of €315.1m in Q1 2024
Pharmaceutical Technology via Yahoo Finance· 3 weeks agoBioNTech has experienced a significant shift in its financial standing, reporting a net loss of €315.1m ($339.3m) in the first quarter (Q1) of 2024. This...
BioNTech SE (NASDAQ:BNTX) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 weeks agoBioNTech SE (NASDAQ:BNTX) Q1 2024 Earnings Call Transcript May 6, 2024 BioNTech SE isn’t one of the...
BioNTech Posts About 50% Drop In Q3 Sales and Profits Amid Falling Demand For COVID-19 Shots
Benzinga via Yahoo Finance· 2 years agoBioNTech SE (NASDAQ: BNTX) has reported Q3 FY22 revenues of €3.46 billion, down from €6.09 billion a...
BioNTech sees UK trials on cancer vaccines starting this year, paper says
Reuters via Yahoo News· 1 year agoClinical trials for BioNTech's cancer vaccines should start this year in Britain, marking an...
BioNTech Stock Surges On Surprise Profit, Strong Sales. But Report Has Downside.
Investor's Business Daily· 7 months agoCovid vaccine maker BioNTech reported a surprise profit and better-than-expected September-quarter...